• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4643668)   Today's Articles (338)   Subscriber (50579)
For: Cassano N, Puglisi Guerra A, Malara C, Loconsole F, Galluccio A, Pezza M, Vena GA. Re-Induction as a Possible Alternative Modality of Dose Escalation of Infliximab: A Prospective Evaluation in a Small Series of Psoriatic Patients. Int J Immunopathol Pharmacol 2016;20:647-50. [PMID: 17880779 DOI: 10.1177/039463200702000324] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]  Open
Number Cited by Other Article(s)
1
Lambert J, Nast A, Nestle FO, Prinz JC. Practical guidance on immunogenicity to biologic agents used in the treatment of psoriasis: What can be learnt from other diseases? J DERMATOL TREAT 2015;26:520-7. [DOI: 10.3109/09546634.2015.1034076] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
2
Treatment of psoriasis: focus on clinic-based management with infliximab. Am J Clin Dermatol 2014;15 Suppl 1:S5-16. [PMID: 24777571 DOI: 10.1007/s40257-013-0054-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
3
Luber AJ, Tsui CL, Heinecke GM, Lebwohl MG, Levitt JO. Long-term durability and dose escalation patterns in infliximab therapy for psoriasis. J Am Acad Dermatol 2013;70:525-32. [PMID: 24388425 DOI: 10.1016/j.jaad.2013.10.059] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2013] [Revised: 10/29/2013] [Accepted: 10/29/2013] [Indexed: 01/23/2023]
4
Mrowietz U, de Jong EMGJ, Kragballe K, Langley R, Nast A, Puig L, Reich K, Schmitt J, Warren RB. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2013;28:438-53. [PMID: 23437792 DOI: 10.1111/jdv.12118] [Citation(s) in RCA: 96] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2012] [Accepted: 01/21/2013] [Indexed: 12/25/2022]
5
Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp S, Reich K, Rosenbach T, Sammain A, Schlaeger M, Sebastian M, Sterry W, Streit V, Augustin M, Erdmann R, Klaus J, Koza J, Muller S, Orzechowski HD, Rosumeck S, Schmid-Ott G, Weberschock T, Rzany B. S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges 2012;10 Suppl 2:S1-95. [PMID: 22386073 DOI: 10.1111/j.1610-0387.2012.07919.x] [Citation(s) in RCA: 210] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
6
German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 2012;304:87-113. [DOI: 10.1007/s00403-012-1214-8] [Citation(s) in RCA: 83] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2012] [Accepted: 01/13/2012] [Indexed: 01/19/2023]
7
Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol 2010;8:696-702.e1. [PMID: 20363366 DOI: 10.1016/j.cgh.2010.03.024] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/19/2009] [Revised: 03/17/2010] [Accepted: 03/21/2010] [Indexed: 02/07/2023]
8
Vena G, Loconsole F, Mastrandrea V, Buquicchio R, Cassano N. Therapeutic hotline: Re-induction may be useful to manage psoriasis relapse during long-term maintenance treatment with infliximab: a retrospective analysis. Dermatol Ther 2010;23:199-202. [PMID: 20415828 DOI: 10.1111/j.1529-8019.2010.01315.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
9
Marchesoni A, Altomare G, Matucci-Cerinic M, Balato N, Olivieri I, Salvarani C, Lotti T, Scarpa R, Vena GA, Valesini G, Giannetti A. An Italian shared dermatological and rheumatological proposal for the use of biological agents in psoriatic disease. J Eur Acad Dermatol Venereol 2010;24:578-86. [DOI: 10.1111/j.1468-3083.2009.03474.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
10
Antoniou C, Stefanaki I, Stratigos A, Moustou E, Vergou T, Stavropoulos P, Avgerinou G, Rigopoulos D, Katsambas A. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre. Br J Dermatol 2009;162:1117-23. [DOI: 10.1111/j.1365-2133.2009.09578.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
11
Puig L, Carrascosa J, Daudén E, Sánchez-Carazo J, Ferrándiz C, Sánchez-Regaña M, García-Bustinduy M, Bordas X, Moreno J, Hernanz J, Laguarda S, García-Patos V. Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos. ACTAS DERMO-SIFILIOGRAFICAS 2009. [DOI: 10.1016/s0001-7310(09)71257-8] [Citation(s) in RCA: 71] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]  Open
12
Spanish Evidence-Based Guidelines on the Treatment of Moderate to Severe Psoriasis with Biologic Agents. ACTA ACUST UNITED AC 2009. [DOI: 10.1016/s1578-2190(09)70086-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
13
Vena G, Galluccio A, De Simone C, Mastrandrea V, Buquicchio R, La Greca S, Dattola S, Guerra AP, Donato L, Cantoresi F, De Pità O, Pezza M, D'Agostino M, Vernaci R, Miracapillo A, Valenti G, Cassano N. A Multicenter Open-Label Experience on the Response of Psoriasis to Adalimumab and Effect of Dose Escalation in Non-Responders: The Aphrodite Project. Int J Immunopathol Pharmacol 2009;22:227-33. [DOI: 10.1177/039463200902200125] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]  Open
14
Fesenkova VI, Kurchenko AI, Castellani ML, Conti P, Anogeianaki A, Caraffa A, Kalogeromitros D. Expression of Co-stimulatory molecules on langerhans cells in lesional epidermis of human atopic dermatitis. Immunopharmacol Immunotoxicol 2008;29:487-98. [PMID: 18075860 DOI: 10.1080/08923970701675101] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA